Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
Department of Paediatrics, Medisch Spectrum Twente, Enschede, The Netherlands.
Trials. 2020 Sep 17;21(1):801. doi: 10.1186/s13063-020-04694-4.
Many asthmatic children suffer from uncontrolled asthma with frequent exacerbations, despite an optimal treatment plan using inhalation medication. Studies have shown that therapy adherence and inhalation technique are often suboptimal in asthmatic children, but these have traditionally been hard to measure. A novel device functioning as an add-on to the inhaler has been developed to measure both aspects by recording vibration patterns during inhalation. This data can be converted to smart feedback and provided to patients immediately via a mobile application. The aim of this study is to improve asthma control in children between 6 and 18 years old by providing immediate smart feedback on the intake of inhalation medication. Asthma control will be measured by forced expiratory volume in 1 s, (Childhood) Asthma Control Test ((c-)ACT) score, and lung function variability and reversibility.
The study will be performed in Medisch Spectrum Twente (Enschede, The Netherlands). The goal is to include 68 uncontrolled moderate to severe asthmatic children between 6 and 18 years old who receive controller inhalation medication through the Nexthaler®, Ellipta®, or Spiromax®. The study consists of three phases. Phase 1 is observational and will last 4 weeks to observe the baseline adherence and inhalation technique as monitored by the add-on device. A randomised controlled trial lasting 6 weeks will be performed in phase 2. Patients in the intervention group will receive immediate smart feedback about the performed inhalations via a mobile application. In the control group, adherence and inhalation technique will be monitored, but patients will not receive feedback. In phase 3, also lasting 6 weeks, the feedback will be ceased for all children and revision of current therapy may occur, depending on the findings in phase 2. Asthma control can be assessed by means of spirometry (both at home and in the hospital) and (c-)ACT questionnaires.
Immediate smart feedback may improve therapy adherence and inhalation technique, and thus asthma control in children and prevent unnecessary switches to targeted biologics. Performing this study in children is desired, since they are known to react differently to feedback and medication than adults.
Dutch Trial Register NL7705 . Registered on 29 April 2019.
许多哮喘儿童尽管采用了吸入药物的最佳治疗方案,但仍存在哮喘控制不佳且经常恶化的情况。研究表明,哮喘儿童的治疗依从性和吸入技术往往不理想,但这些问题传统上难以衡量。一种新型装置已被开发出来,可以通过记录吸入过程中的振动模式来测量这两个方面。这些数据可以转换为智能反馈,并通过移动应用程序立即提供给患者。本研究旨在通过提供吸入药物摄入的即时智能反馈来改善 6 至 18 岁儿童的哮喘控制。哮喘控制将通过 1 秒用力呼气量(儿童哮喘控制测试(c-ACT)评分)、肺功能变异性和可逆性来衡量。
该研究将在特温特医疗中心(荷兰恩斯赫德)进行。目标是纳入 68 名接受 Nexthaler®、Ellipta®或 Spiromax®控制吸入药物治疗的 6 至 18 岁未控制的中重度哮喘儿童。该研究分为三个阶段。第 1 阶段是观察性的,持续 4 周,以观察通过附加装置监测的基线依从性和吸入技术。第 2 阶段将进行为期 6 周的随机对照试验。干预组患者将通过移动应用程序立即获得关于吸入操作的智能反馈。在对照组中,将监测依从性和吸入技术,但患者不会收到反馈。在第 3 阶段,所有儿童的反馈也将停止 6 周,根据第 2 阶段的结果可能会对当前治疗进行修订。可以通过肺活量测定法(在家中和医院)和(c-ACT)问卷评估哮喘控制。
即时智能反馈可能会改善治疗依从性和吸入技术,从而改善儿童的哮喘控制并防止不必要地转为靶向生物制剂。之所以希望在儿童中进行这项研究,是因为与成人相比,他们对反馈和药物的反应不同。
荷兰试验注册 NL7705。于 2019 年 4 月 29 日注册。